COCOON shows lazertinib lead-in plus simplified prophylaxis reduced grade ≥2 skin toxicity to 18% with SC amivantamab in EGFR ...
At the Community Oncology Global Congress (COGC 2026), organized by OncoDaily, Amol Akhade, Senior Consultant in Medical ...
VIKTORIA-1 shows gedatolisib maintained strong PFS benefit over alpelisib in PIK3CA-mutant HR+/HER2− breast cancer, including ...
CROWN ctDNA data link early lorlatinib progression to genomic complexity, TP53 and bypass pathways rather than new ALK ...
MONARCH shows median OS of 32.1 vs 24.6 months with abemaciclib after prior CDK4/6 therapy, but the survival difference was ...
FOURLIGHT-1 shows atirmociclib plus fulvestrant improved PFS to 9.4 vs 6.6 months after prior CDK4/6 inhibition in HR+/HER2− ...
VOLGA at ESMO 2026: Perioperative Durvalumab With or Without Tremelimumab Plus Enfortumab Vedotin in MIBC ...
VOLGA at ESMO 2026: Perioperative Durvalumab With or Without Tremelimumab Plus Enfortumab Vedotin in MIBC ...
What Changed in Melanoma Immunotherapy Over 20 Years? / cancer, ESMO, immune response, Melanoma, Nicholas Restifo, OncoDaily, ...
AI Can Guide Cancer Drug Discovery, but Clinical Validation Still Matters / AI, artificial intelligence, cancer, clinical ...
Izalontamab Brengitecan Improves PFS in HR+/HER2− Breast Cancer in China / Bihui Li, Bin Liu, Bing Zhao, Binghe Xu, cancer, ...
Princess Ghida Talal։ Our Heartfelt Thanks to Everyone Who Believed in Our Mission and Stood by Our Patients / cancer, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results